FDA starts review of Roche’s eye disease drug, setting up 2022 verdictThe FDA has started a priority review of Roche’s bispecific antibody faricimab for two major causes of blindness, Share XFDA starts review of Roche’s eye disease drug, setting up 2022 verdicthttps://pharmaphorum.com/news/fda-starts-review-of-roches-eye-disease-drug-setting-up-2022-verdict/
Roche eyes October decision by FDA for wet AMD implantThe FDA has started a review of a new implant version of Roche’s ranibizumab therapy for wet age-related Share XRoche eyes October decision by FDA for wet AMD implanthttps://pharmaphorum.com/news/roche-eyes-october-decision-by-fda-for-wet-amd-implant/
UK patient group warns COVID could limit access to Novartis’ new eye drugNICE has recommended regular NHS funding for Novartis’ long-acting eye drug Beovu (brolucizumab) in England and Wales – Share XUK patient group warns COVID could limit access to Novartis’ new eye drughttps://pharmaphorum.com/news/patient-group-warns-covid-limit-access-novartis-eye-drug/
Novartis taps smartpatient for app to support wet AMD patientsGerman digital health company smartpatient is adding a new section of its MyTherapy app providing information on wet Share XNovartis taps smartpatient for app to support wet AMD patientshttps://pharmaphorum.com/news/novartis-taps-smartpatient-for-app-to-support-wet-amd-patients/
Novartis’ Beovu safety woes could cost billions of dollars, says analystThe launch of Novartis’ Beovu ophthalmology drug could be compromised after a safety warning from doctors over several Share XNovartis’ Beovu safety woes could cost billions of dollars, says analysthttps://pharmaphorum.com/news/novartis-beovu-launch-could-be-hit-by-safety-warning/
Novartis’ blockbuster hope Beovu clears EMA advisory panelNovartis could launch its new age-related macular degeneration drug in Europe early next year after getting a green Share XNovartis’ blockbuster hope Beovu clears EMA advisory panelhttps://pharmaphorum.com/news/novartis-blockbuster-hope-beovu-clears-ema-advisory-panel/
